Global Biologics CDMOs: 2025 Public Market Overview

Global players

Selective capacity optimization

In 2025, large global CDMOs prioritized optimization of existing networks over broad footprint expansion. Capital was directed toward constrained parts of the value chain, most notably sterile drug-product manufacturing and selected advanced therapy platforms as well as automation and debottlenecking initiatives aimed at increasing effective capacity rather than installed capacity.

Investments focused on constrained manufacturing nodes, particularly sterile drug-product operations and advanced therapy platforms, as well as automation and throughput improvements that increased effective capacity. For example, Samsung Biologics advanced the commissioning of Plant 5 at its second Bio Campus, which began operations in April 2025, adding capacity within an already established manufacturing cluster rather than developing a new standalone site. Similarly, WuXi Biologics added microbial manufacturing capability (Q2 2025) and expanded drug-product manufacturing (Q3 2025) in Singapore, illustrating capability densification within established hubs.

Integrated end-to-end service models

Global platforms continued strengthening integrated service offerings, spanning development, scale-up, commercial manufacturing, and lifecycle management. As biologics pipelines matured and supply chains became more complex, sponsors increasingly favored CDMOs capable of coordinating programs across multiple sites within a single network, reducing transfer risk and ensuring continuity from clinical to commercial stages.

This integration theme was visible in Daewoong Bio’s build-out of end-to-end biologics manufacturing services in Q3 2025, as well as Piramal Pharma’s Q2 2025 expansion of its US-based integrated CDMO platform; both reinforced network cohesion rather than geographic proliferation.

Capability-focused acquisitions and partnerships

Deal activity among global players in 2025 was largely capability-driven rather than scale-led. Acquisitions and partnerships targeted specific technologies, advanced modality expertise, fill-finish capacity, or strategic geographic infill within established networks. The prevailing objective was to strengthen differentiation and technical depth in high-growth segments, particularly advanced therapies and sterile manufacturing, rather than to pursue broad consolidation for size alone.

This shift was reflected in targeted transactions such as PCI Pharma Services’ acquisition of Ajinomoto Althea, which added specialized aseptic fill–finish capacity and technical expertise in sterile drug product manufacturing, reinforcing PCI’s positioning in a constrained and high-value segment of the value chain. Similarly, BBG Advanced Therapies’ transatlantic partnership with CELLforCURE by SEQENS focused on expanding access to complementary advanced therapy manufacturing capabilities across the US and Europe, enabling broader support for cell and gene therapy (CGT) programs without requiring large-scale platform consolidation. These deals illustrate that CDMOs and manufacturing partners increasingly prioritize access to specific technical capabilities and modality-specific expertise, reflecting the growing importance of specialized manufacturing nodes in supporting complex biologics and advanced therapy pipelines.

Regional players

Geographic diversification relevance

In 2025, regional CDMOs gained strategic relevance as sponsors increasingly prioritized geographic redundancy and localized manufacturing capacity within broader supply models. Rather than serving as standalone competitors to global platforms, regional providers functioned as complementary nodes within multi-site manufacturing strategies, particularly for drug-product, fill-finish, and late-stage biologics programs where proximity to end markets and regulatory familiarity are critical.

Notably, OmniaBio expanded domestic CGT manufacturing capacity in Canada in Q1 2025, supported by public funding aimed at strengthening national biomanufacturing capabilities. Similarly, DINAMIQS opened Switzerland’s first national current good manufacturing practice (cGMP) viral vector facility in Q4 2025, reinforcing sovereign manufacturing infrastructure in advanced therapies. Both developments illustrate how regional investments in 2025 were often aligned with government-backed resilience strategies and sponsor interest in distributed production models.

Operational modernization and digitalization

Beyond geographic positioning, regional players concentrated capital on modernization and process improvement rather than breakthrough platform development. Investments typically targeted facility upgrades, automation, quality system enhancement, and digitalization of process controls. For example, in February 2025, Recipharm commissioned a new modular sterile filling system at its facility in Wasserburg, Germany, to enhance automated aseptic production flexibility. In June 2025, the company deployed a process analytical technology platform (“QC on Wheels”) to embed real-time analytics into manufacturing execution, improving data integrity and execution reliability. Later, in October 2025, Recipharm expanded parenteral development and sterility laboratories in Bengaluru, India, reinforcing global quality and compliance frameworks. Meanwhile, Delpharm earmarked ~$220 million in 2025 for capacity expansion and modernization of its sterile and finished dosage operations in Quebec, Canada, with modern infrastructure and automation supporting throughput efficiency and inspection readiness.

Long-term program alignment

Growth across the regional segment was increasingly anchored in repeat programs and longer-duration agreements, providing improved visibility into utilization stability. As sponsors structured supply models with embedded redundancy, regional platforms positioned themselves as dependable contributors within broader manufacturing ecosystems. In 2025, this translated into steady, utilization-led expansion rather than rapid footprint growth, reinforcing the segment’s role as a stabilizing component of the biologics outsourcing landscape. This dynamic was reflected in several targeted agreements during the year. In March 2025, Fujifilm Biotechnologies expanded long-term commercial manufacturing support agreements with multiple biologics sponsors across its European network, reinforcing sustained utilization of existing biologics production capacity. In May 2025, PCI Pharma Services’ acquisition of Ajinomoto Althea was accompanied by the continuation of existing client manufacturing programs, providing immediate backlog visibility tied to sterile fill–finish supply commitments.

Specialized manufacturers

Advanced therapy and high-complexity focus

Specialized CDMOs in 2025 remained concentrated on technically demanding segments such as viral vectors, plasmid DNA, CGTs, and bioconjugates. Unlike the rapid platform build-outs observed earlier in the decade, the emphasis shifted toward scaling and operationalizing established infrastructure.

Companies focused less on announcing new sites and more on strengthening execution within high-barrier modalities where manufacturing expertise, regulatory compliance, and process reproducibility are critical differentiators. For example, in August 2025, ProBio, a CDMO specialized in CGTs, expanded its GMP plasmid DNA production and adeno-associated virus vector manufacturing capabilities following the launch of its 128,000 square feet facility in Hopewell, New Jersey. Investment priorities shifted toward the demand for highly specialized manufacturing expertise, particularly in oncology and advanced therapeutic platforms, where technical barriers to entry remain high.

Vertical supply chain integration

In 2025, vertical integration became a strategic priority for specialized CDMOs operating in high-complexity modalities. Rather than relying on fragmented supplier networks for critical components, companies increasingly moved to internalize upstream inputs such as plasmid DNA production, viral vector intermediates, and bioconjugation steps. This shift was driven by the need to mitigate supply risk, improve process control, and enhance comparability across batches.

By bringing sensitive inputs in-house, specialized manufacturers reduced exposure to external bottlenecks and gained tighter oversight over quality, scheduling, and regulatory documentation. In technically demanding segments where minor variability can materially affect product performance, vertical integration strengthened both operational resilience and sponsor confidence.

Process reliability and platform refinement

The competitive landscape for specialized CDMOs in 2025 was shaped less by capacity access and more by execution quality. Following several years of rapid platform build-out across advanced modalities, attention shifted toward how effectively those capabilities could be deployed at scale. Investment priorities increasingly centered on analytical depth, automation, process characterization, and quality system reinforcement rather than incremental infrastructure expansion.

For specialized manufacturers, differentiation evolved accordingly. The ability to demonstrate reproducibility across batches, validated process control strategies, and regulatory robustness became critical in securing later-stage programs. In high-complexity segments such as viral vectors and CGTs, operational reliability, not merely technical capability, emerged as the defining competitive factor, signaling a maturation phase within the advanced biologics outsourcing market.

Emerging players

Targeted market positioning

Emerging CDMOs in 2025 generally adopted focused and deliberately constrained growth strategies. Rather than attempting to replicate the integrated, multi-site models of global providers, these companies entered the market through clearly defined niches, whether modality-specific manufacturing, early-stage biologics support, or regionally anchored production services. Their investment profiles reflected limited capital flexibility and a need to demonstrate credibility within a specific segment before expanding scope. As a result, capacity additions were typically modular, staged, and aligned to identifiable customer programs rather than broad platform build-outs.

Niche differentiation strategies

Competitive positioning among emerging players was centered on specialization. Instead of competing on breadth of services, these companies differentiated through flexibility, technical focus, or cost structure advantages within narrow value-chain segments such as early clinical biologics supply, plasmid production, peptide intermediates, or regional CGT support. This approach allowed them to build reputation and recurring customer relationships without overextending balance sheets. Scaling, where it occurred, was incremental and capability-specific rather than network-wide.

Path to operational breakeven

Financial sustainability remained a central priority across the emerging CDMOs segment. In a more selective funding environment, these companies faced greater pressure to align capital deployment with revenue visibility. Investments were increasingly tied to secured programs, partnership-backed growth, or milestone-triggered expansions. The emphasis shifted from capacity signaling to operational execution, with demonstrable utilization, regulatory compliance, and reproducibility as prerequisites for attracting longer-term contracts and future capital.